14th Dec 2023 14:25
Aptamer Group PLC - York-based biotech firm - Signs material agreement with unnamed biotechnology company, focused on developing genetic medicines. Aptamer will use its platform to discover Optimer binders to enable specific targeting of genetic medicines to specific cell types. Says it will receive up to GBP553,000 in development fees for discovering and developing the Optimer binders. Work is expected to start shortly and is expected to be completed within the current financial year. Optimer binders are a novel class of molecules for selectively targeting new biomarkers and tissues. Chief Technical Officer Arron Tolley says: "This project builds on the work we have been doing in drug delivery since being refunded and supports the need for new delivery modalities within the genetic medicines space. Targeting oligonucleotide therapeutics beyond hepatocytes remains a challenge across the industry; we believe the properties of Optimers make them suitable for developing precision-guided therapies and that Optimer-targeted therapies may represent the next stage in targeted drug delivery."
Current stock price: 1.23 pence, up 2.3%
12-month change: down 98%
By Sabrina Penty, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Aptamer Group